Corticotropin-releasing hormone (CRH) is a major regulator of the hypothalamic-pituitary-adrenal axis. Binding to its receptor CRHR1 triggers the downstream release of the stress response-regulating hormone cortisol. Biochemical, behavioral and genetic studies revealed CRHR1 as a possible candidate gene for mood and anxiety disorders. Here we aimed to evaluate CRHR1 as a risk factor for panic disorder (PD). Allelic variation of CRHR1 was captured by 9 single-nucleotide polymorphisms (SNPs), which were genotyped in 531 matched case/control pairs. Four SNPs were found to be associated with PD, in at least one sub-sample. The minor allele of rs17689918 was found to significantly increase risk for PD in females after Bonferroni correction and furthermore decreased CRHR1 mRNA expression in human forebrains and amygdalae. When investigating neural correlates underlying this association in patients with PD using functional magnetic resonance imaging, risk allele carriers of rs17689918 showed aberrant differential conditioning predominantly in the bilateral prefrontal cortex and safety signal processing in the amygdalae, arguing for predominant generalization of fear and hence anxious apprehension. Additionally, the risk allele of rs17689918 led to less flight behavior during fear-provoking situations but rather increased anxious apprehension and went along with increased anxiety sensitivity. Thus reduced gene expression driven by CRHR1 risk allele leads to a phenotype characterized by fear sensitization and hence sustained fear. These results strengthen the role of CRHR1 in PD and clarify the mechanisms by which genetic variation in CRHR1 is linked to this disorder.
INTRODUCTION
The hypothalamic-pituitary-adrenal (HPA) axis with its primary effector cortisol has a central role in the response to stress and disorders relating to it, such as mood and anxiety disorders. The neurobiological and neurofunctional mechanisms that lead to these disorders are, however, elusive. The present study therefore aimed to link genetic variation in the HPA system to the clinical phenotype by utilizing a multilevel approach, in which genetic variants were linked to molecular, physiological, neural and behavioral data relating to panic disorder (PD).
Disruptions of internal homeostasis or exposure to external threat activate the HPA axis, triggered by the secretion of corticotropinreleasing hormone (CRH). Binding to the CRH receptor (CRHR), it stimulates the release of corticotropin (adrenocorticotropic hormone) in the pituitary gland and thus leads to increased levels of cortisol. 1, 2 Two different forms of CRHR (CRHR1 and CRHR2) exist, which differ in expression pattern. 3 CRHR1 function has been examined in detail in mice where the Crhr1 gene has been knocked out (Crhr1 − / − ). In global Crhr1 − / − mice, stress-induced adrenocorticotropic hormone and cortisol levels were markedly blunted, anxiety was decreased and exploratory as well as locomotor behavior was increased. 4 To dissect the role of Crhr1 in specific brain regions, conditional knockout mice were generated, where the gene was only deleted in brain regions expressing CaMKIIα, that is, the forebrain and the limbic system. In contrast to global knockout mice, these animals were hypersensitive to stress 5 but had normal spatial memory and hippocampal morphology following chronic social defeat stress, 6 arguing that these negative effects of stress are mediated by forebrain Crhr1. Ablation of Crhr1 in the hippocampus prevented the downregulation of the glucocorticoid receptor after stress and did not display stressinduced sequelae in adulthood following early life stress. 7 These data suggest an important role of CRHR1 in short-and long-term adaptive responses to stress, probably by attenuating the impact of circulating adrenocorticotropic hormone and cortisol, while CRHR1 directly exerts negative effects on learning and hippocampal morphology as a response to stress. Further adding to this, it was shown that limbic CRHR1 enhances the consolidation of fear memories. 8 There is ample evidence suggesting that the CRH/CRHR system is crucially involved in mood and anxiety disorders. 2, [9] [10] [11] [12] Accordingly, targeted association studies were conducted to test whether CRHR1 polymorphisms-mainly rs7209436, rs110402 and rs242924, forming a haplotype where the TAT combination conveys diseaseinfluence the risk for stress-related disorders, such as posttraumatic stress disorder 13, 14 and depression. [15] [16] [17] [18] [19] [20] In line with this, CRHR1 is associated with the stress-sensitive personality trait Neuroticism 21 and depression-related measures such as the Beck Depression Inventory. 22 Most noteworthy, there is consistent evidence that genetic variation interacts with early adverse life events to increase risk for depression. [15] [16] [17] [22] [23] [24] [25] In the context of PD, linkage and case/ control studies as well as dimensional association studies provided a heterogeneous picture [26] [27] [28] [29] regarding an involvement of CRHR1. Notably, the initial association of this gene with PD 29 was followed up recently, providing evidence that the CRHR1 minor rs878886 allele leads to fear-acquisition deficits using a fear-conditioning protocol in healthy volunteers. 30 Furthermore, a neuroimaging study revealed that the processing of emotional stimuli crucially depends on CRHR1 genotype. 31 Thus one can assume that CRHR1 genotype predisposes towards PD; however, conclusive evidence and the precise mechanisms are still elusive. The combination of CRHR1 genetics with neurofunctional and behavioral data can provide deeper insight into the etiology of PD. To address these issues, we aimed to further clarify the contribution of presumably functional CRHR1 polymorphisms to PD. To do so, a multilevel approach was applied, by (1) genotyping nine CRHR1 tag singlenucleotide polymorphisms (SNPs) and determining their corresponding haplotypes in two independent, case-control samples, (2) assess the effect of significantly associated SNPs on mRNA expression in human postmortem brain, (3) examining the effect of these SNPs on functional magnetic resonance imaging (fMRI) brain activation correlates of fear conditioning in patients with PD, (4) testing the association of risk SNPs on parameters indicating defensive reactivity during a behavioral avoidance task (BAT) such as flight behavior, autonomic indices of anxiety (heart rate) and reported levels of anxiety, (5) studying the effect of significant SNPs on basal scores of dimensional anxiety traits and finally (6) compute possible SNP function using various bioinformatical tools.
MATERIALS AND METHODS Samples
The discovery sample described, 32 consisted of 239 unrelated PD patients recruited in Germany (female = 143; mean age 37.6 ± 11.1 years). Diagnosis of PD and the presence of comorbid agoraphobia (PD/AG = 68.6%) and major depression (PD/MD = 26.4%) was ascertained by experienced psychiatrists on the basis of medical records and structured clinical interviews (Composite International Diagnostic Interview) according to the criteria of Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised (DSM-III-R) or DSM-IV, respectively. [33] [34] [35] Sex-matched controls comprised 239 blood donors (female = 143; mean age 36.2 ± 11.8 years) of German descent who were not screened for the absence of mental disorders owing to anonymity requirements.
The replication patient sample (n = 292; female = 216; mean age 36.0 ± 10.8 years) was obtained from the national research initiative 'Panic-Net' funded by the Federal Ministry of Education and Research; 36 sample details have been published elsewhere. 32, 37 Diagnosis of PD/AG (100%) and comorbid MD (33.2%) was established by a structured clinical interview (Composite International Diagnostic Interview) according to DSM-IV criteria. 35 All patients were free of medication. Control subjects (n = 292; female = 216; mean age 28.8 ± 7.4 years) were drawn and matched from a larger number of screened healthy controls (n = 581; female = 408; mean age 25.4 ± 6.4 years). Absence of mental axis one disorders was established by experienced psychologists on the basis of the Mini International Neuropsychiatric Interview 38 according to the criteria of DSM-IV. 35 For both patients and controls, agoraphobic traits and anxiety sensitivity were evaluated by German versions of the Agoraphobic Cognitions Questionnaire (ACQ) 39 and the Anxiety Sensitivity Index (ASI). 40 For replication of dimensional findings, 893 further screened healthy controls (female = 496; mean age 25.4 ± 5.2 years) were recruited on the same conditions as the controls described in detail above. For this second control sample, additionally the Anxiety Sensitivity Index 3 (ASI3) 41 with its three subscales Social Concerns, Physical Concerns and Cognitive Concerns were collected.
Patients with schizoaffective or other psychotic disorders, comorbid substance abuse disorders, mental retardation, neurological, neurodegenerative disorders and relevant somatic comorbidities were excluded. Only patients and volunteers who gave written informed consent were enrolled in the study, which complied with the Declaration of Helsinki and was approved by the respective local Ethic Committee.
For 
Genetic analysis
For information on SNP selection 43 and genotyping, see Supplementary Methods and Supplementary Table S1. SNP and haplotype associations were calculated by two-sided χ 2 -tests and adjusted for multiple testing using Bonferroni correction, that is, within each (sub-) sample nominal SNPs were corrected for 32 tests (8 SNPs × 2 genetic models × 2 sexes) and haplotypes for 20 tests (number of haplotypes (block 1+block 2) × 2 sexes) on a minimal set of 8 informative CRHR1 SNPs (PLINK V1.07). 44 Haplotype blocks were defined according to the solid spine method (HaploView V4.2). 45 In this analysis setting, we achieve a power of 36% in the discovery sample, 42% in the replication sample and 65% in the combined sample to detect SNP and haplotype associations, respectively, conveying a relative risk of 1.5 to develop PD assuming a co-dominant model and a minor allele frequency of 0.05. 46 SNPs that remained significant after Bonferroni correction were further analyzed.
Expression analysis
To analyze the influence of CRHR1 polymorphisms on gene expression in the MRC sample, we carried out analyses of variance on normalized mean expression values in a genotypic model. Allele-specific changes of gene expression were examined with linear regressions. Detailed Information on mRNA isolation, quantification and normalization of raw data 47, 48 are given in Supplementary Methods.
Functional MRI
The task design and analyses have been detailed elsewhere. 49, 50 Whole-brain fMRI analyses were carried out in 48 patients of the replication sample, where we tested for genotype effects on (1) differential conditioning processes in the early acquisition phase and (2) on safety signal processing. [51] [52] [53] For detailed methodical information, see Supplementary Methods and Supplementary Table S2 .
Behavioral avoidance test
The BAT procedure is reported elsewhere. 54 Results were obtained from 147 patients (BAT sample) of the replication sample; defensive reactivity was indexed by intensity of self-reported anxiety on a visual analog scale (1-10), autonomic arousal as measured by heart rate (in b.p.m.) and fearrelated behavior (escape from the test chamber at o 10 min of exposure). Further information is given in Supplementary Methods and Supplementary Table S3 .
Panic-relevant psychometric traits: ASI, ASI3, ACQ Associations of minor allele dosages with dimensional anxiety traits were analyzed with linear regressions modeling the ACQ, the ASI and the ASI3 sum scores. Throughout the manuscript, P-valueso0.05 indicate significant associations.
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RESULTS

Genetic analysis: single-and multi-marker associations
Single-and multi-marker associations were first calculated using the discovery sample (Supplementary Tables S4 and S5) , next using an independent replication sample (Supplementary Tables  S6 and S7 ) to confirm the results and finally with the combined (discovery plus replication) sample to obtain maximal power (Tables 1 and 2 ). To confirm the specificity of associations with PD, the respective polymorphisms were further analyzed in individuals with and in those without comorbid depression (Supplementary  Table S8 ).
Of the eight single markers that passed inclusion criteria, rs7209436, rs12936181, rs17689918 and rs17689966 were associated with PD. The major risk allele (C) of rs7209436 was not associated with disease in one of the individual samples, yet it became nominally significant in females in the combined data set owing to increased power. In contrast, the major allele (T) of rs12936181 conveyed genetic risk exclusively in males; this was true for the discovery and the combined but not the replication sample. The strongest association was found for rs17689918, whose minor allele (A) was significantly enriched in cases as compared with unaffected individuals. This allelic association, first detected in the female subset of the discovery sample, withstood Bonferroni correction in females of the replication and combined sample as well as in the total combined sample. Finally, the minor allele (G) of rs17689966 marginally increased the risk for PD in females of the discovery sample but nominally in the replication and the combined sample.
The examined SNPs were in considerable linkage disequilibrium allowing the definition of two haplotype blocks ( Figure 1 ). In block 1, the CGTGA haplotype, containing all three risk alleles of rs7209436, rs12936181 and rs17689918, was nominally enriched in the replication and combined samples and remained significant after Bonferroni correction in both female subsets. In contrast, the CGCGG haplotype, comprising the rs7209436 risk allele as well as the both protective alleles of rs12936181 and rs17689918, was found to have a protective effect in males in the discovery and the combined samples at the nominal level. In the second block, consisting of rs17689966 and rs4792825, the GA haplotype was nominally associated with PD in the female discovery and replication subsamples as well as in the total combined sample; the combined female subset revealed a Bonferroni-resistant association. Accordingly, the AA haplotype of block 2, including the protective rs17689966 A-allele, nominally reduced the risk toward PD in females of the replication and the combined subsample.
Expression analysis Significant allele-and genotype-specific differences of rs17689918 on mRNA expression levels were found in the forebrain (N = 60; AA = 1/AG = 20/GG = 39) and the amygdalae (N = 58; AA = 2/AG = 20/GG = 36), where the minor risk allele reduce the mean expression of CRHR1. In the midbrain (N = 43; AA = 0/AG = 13/GG = 30), no effect of genotype on expression was detected (Supplementary Table S9 ).
Functional MRI Alleles and genotypes of rs17689918 had significant effects on differential conditioning and safety learning. Analyses were first performed across the total fMRI sample (rs17689918: n = 19A, n = 29 G/G). In a second step, the small male sample has been excluded, to reduce group variability owing to sex differences (remaining female sample: n = 16A, n = 17 G/G). For differential conditioning (CS+ unpaired 4CS − ), activation in bilateral frontal cortices was reduced in risk (A) allele carriers (Figure 2 ; Supplementary Table S10). For safety signal processing, (CS − 4 baseline (fixation cross)) activation of the amygdala was increased in risk allele carriers; this effect was detectable only in a region of interest analysis in females (Figure 2 ; Supplementary Table S11) . Together, these data provide support for aberrant differential conditioning and safety signal processing modulated by the rs17689918 risk allele.
Behavioral avoidance test PD/AG patients carrying at least one risk allele of rs17689918 showed less frequent escape behavior as compared with non-risk allele homozygotes (Figure 3a) . The association marginally failed to reach statistical significance in the whole patient sample (χ 2 = 3.09; P = 0.08) but was significant in the female subgroup (χ 2 = 3.78; P = 0.05). The reduced behavioral tendency to flee from the acute exposure in rs17689918 risk allele carriers was accompanied by a smaller heart rate increase during the challenge (genotype F(1, 117) = 5.03, P = 0.027; Figure 3b ) in both escaping and non-escaping patients (genotype × behavioral group F(1, 117) = 1.16; P = 0.284). No significant associations were found for heart rate during anticipation and recovery periods, suggesting a specific effect during the threat challenge. Importantly, the subjective distress during the task was comparable between genotype groups (Figure 3c ). The observed dissociations between physiological/behavioral and subjective responses depending on genotype were supported by the following results: in the non-risk genotype patient group, subjective anxiety ratings during exposure were strongly correlated with initial heart rate increase from last minute of anticipation to first minute of exposure (r = 0.627, P o0.001) and overall exposure heart rate (r = 0.378, P = 0.001), suggesting synchrony between physiological and verbal responses; in contrast, heart rate responses did not predict subjective ratings in risk allele carriers (initial heart rate increase: r = 0.215, P = 0.134; overall heart rate: r = 0.239; P = 0.091).
Panic-relevant psychometric traits: ASI, ASI3, ACQ To validate whether risk and protective alleles influenced dimensional measures of anxiety associated with PD/AG, we analyzed rs17689918 for its effect on the ASI and the ACQ in the replication sample and an independent second control sample for which additional ASI3 data were available (Supplementary Table  S12 ). In line with results from categorical outcomes, rs17689918 led to an increased ASI sum score by 2.17 (P = 0.033) points per A (risk) allele in the combined sample (that is, cases and controls) and by 2.42 points per A (risk) allele (P = 0.040) in the combined female subset. Allelic influence on the ASI sum score could not be replicated in the independent second control sample but indirectly on the ASI3 sum score in females (1.89 points per A allele; P = 0.006), which represents the same phenotype. Furthermore, the minor A allele of rs17689918 significantly increased sum scores of the both ASI3 subscales, social concerns (1.02 points per A allele; P = 0.004) and cognitive concerns (0.72 points per A allele; P = 0.050) in females as well. A significant effect of rs17689918 alleles on the ACQ sum score was only found in female controls: each A allele led to an average reduction of 0.075 points. In the second control sample, there was no detectable impact of rs17689918 on ACQ sum scores.
Bioinformatical assessment of SNP function Because of the high consensus of categorical, dimensional, psychophysiological and brain imaging data, the intronic polymorphism rs17689918 seem to have a putative role in CRHR1 gene function. To identify its possible influence on splice junctions, we analyzed rs17689918 with the Human Splicing Finder V2.4.1 (Desmet et al.
55
) and found that the minor risk allele replaces two binding sites for the Intronic Splicing Enhancers SF2/ASF and SRp55 by a new binding site for SC35. Furthermore, we found for rs17689918 90 perfect proxies (r 2 = D' = 1), which also affect neighboring genes
Variants of CRHR1 predispose to panic disorder H Weber et al Table 1 . Association results for examined SNPs along with their minor/major alleles (converted to the coding strand), genotype and allele frequencies in percentage for cases and controls, the nominal and the Bonferroni-corrected (in brackets) association P-values for the combined sample, as well as the combined female and male subsamples
Combined sample (N = 531) Combined female sample (N = 359) Combined male sample (N = 172) 56 and implied allele-specific changes in transcript splicing (n = 20). Also, polymorphisms with deleterious effects on the coding sequence (n = 5; Patrocles database) 57 were found in the adjacent genes (Figure 1b ; Supplementary Table S13) .
DISCUSSION
In the present study, we applied a multilevel approach to characterize the role of CRHR1 in PD and thereby demonstrated that alleles in CRHR1 (1) increase the risk towards PD in females, (2) go along with reduced expression of the gene product in the forebrain and amygdala, accounting for (3) reduced frontal cortical activation upon fear conditioning as well as increased amgydala activation as a response to safety signal presentation while (4) increasing de-synchrony between physiological arousal, escape behavior and reported fear-an index of increased severity of the disorder and (5) increasing anxiety sensitivity. This comprehensive body of results provides evidence on how CRHR1, as part of the HPA axis might contribute to PD and confirms a previously reported finding that allelic variation in the CRHR1 gene is associated with PD. 29 For replication of the CRHR1 locus, we analyzed eight tagSNPs in two independent case/control samples. Our approach goes along with several limitations: compared with other common psychiatric disorders, the examined sample sizes are of only moderate size; however, the symptomatology of PD restricts openness to study participation. Also, the composition of discovery and replication samples differs slightly: in the former, patients were compared with apparently healthy blood donors, whereas in the latter affected individuals were compared with screened controls. The discovery approach is thus more conservative, as the potential misclassification of estimated 11 individuals in the discovery control sample (assuming a 5% prevalence of PD) 58 decreases potential differences between analysis groups. Furthermore, only patients of the replication sample were free from medication. Thus imaging and behavioral genetics studies could potentially not fully be generalized to the discovery sample, although replicated findings with these methods would be desirable. All these aspects limit the power of the genetic analysis; nevertheless, four of the analyzed polymorphisms were found to be associated with PD. rs7209436, which tags rs110402 and rs242924, represents the frequently investigated TAT-haplotype known to predispose to depression 15, 16, 22, 23 but displayed only suggestive association signals with female PD patients. In line with this, rs7209436 was not associated with PD in two further independent studies. 28, 29 Although smaller sample size and mixed-sex analysis may explain this, a comparably small sample revealed a strong association with depression. 15 Exploratory analyses of our PD subsamples with and without comorbid MD (see Supplementary Table S8 ) support the hypothesis that this polymorphism may specifically influence the risk towards depression but not anxiety disorders. For those SNPs that revealed the strongest associations with PD in our current study-rs17689918 and rs17689966-there is already indirect evidence for effects in anxiety disorders: on the one hand, rs17689918 is in linkage disequilibrium with two nominally associated SNPs (rs1396862 and rs1876831) as well as rs878886, the top finding of the Keck study on PD. 29 On the other hand, rs17689966 has been reported to predispose to posttraumatic stress disorder.
14 Here depression comorbidity subsample analyses showed no exclusive association, arguing for a PD-specific effect of rs17689918 and rs17689966 (see Supplementary  Table S8 ). Quantitative real-time PCR demonstrated that rs17689918 reduced CRHR1 expression in the amygdala and forebrain, regions known to regulate anxiety. Furthermore, a recent study to detect functional variation in the human genome 59 classified rs17689918 SNP as expression quantitative trait locus Table 2 . Association results for haplotypes examined in the combined sample, as well as male and female subsamples For each (sub) sample, we show the cumulated posterior probabilities for all haplotypes per block (N P ), relative haplotype frequencies in the analysis groups and nominal as well as Bonferroni-corrected (in brackets) association P-values.
Bold indicates Po0.05 in at least one sample. All P-values were rounded to the third decimal place.
Variants of CRHR1 predispose to panic disorder H Weber et al (eQTL). Moreover, CRHR1 expression, together with that of LRRC37A, LRRC37A2 and LRRC37A4P, was influenced by rs17689918 at the genome-wide significance level (Po5 × 10
), with CRHR1 being the closest gene to the eQTL. This finding is corroborated by two other studies examining human brain tissue: in the cerebellum, the minor rs17689918 allele results in significantly reduced CRHR1 expression, 60 while in the cortex perfect proxies (namely rs17763533, rs17649954, rs916793 and rs17571739) of the untyped rs17689918 were found to have the same effect. 61 Although our genetic associations were mainly driven by females, the eQTL function of rs17689918 was confirmed with our brain expression sample, which is biased toward male donors. The previously observed general (that is, gender independent) eQTL function of rs17689918 (Lappalainen et al. 59 ) is, however, no contradiction to our findings. Rather, it excludes the possibility that upstream regulatory processes are responsible for the observed gender difference. Instead, males may exhibit a tolerance toward rs17689918-dependent CRHR1 expression. However, despite our data argue for reduced CRHR1 expression leading to PD, extended linkage disequilibrium at this locus suggests that also neighboring risk genes of psychiatric disorders (C17orf69, IMP5 and MAPT) may predispose to PD as well. However, this hypothesis needs independent replication to support its validity.
The multilevel approach utilized in the present study allows to shed light on the neural mechanisms leading from molecular changes to disease phenotype. Recently, we found evidence that the two central clinical symptom complexes of PD, namely acute panic and chronic anxious apprehension, reflect different stages of defensive reactivity as suggested by animal models; 54 see also review by Hamm et al. 62 In this view, acute panic and associated escape behavior can be conceptualized as defensive behaviors during imminent threat as both clinical states of panic and escape, respectively, and acute threat processing were characterized by Figure 1 . Linkage disequilibrium (LD) plot of CRHR1 (a) in the combined sample (N = 531). LD is displayed as D' haplotype blocks, which were defined using the solid spine method. In red, single-nucleotide polymorphisms (SNPs) (rs110402 and rs242924) of the TAT haplotype, 29 which were not genotyped, are indicated. SNPs that are framed and highlighted in blue were found to be significantly associated with panic disorder. Allele-specific functional predictions of rs17689918 and its 90 perfect proxies (D' = r 2 = 1) are shown (b). Predicted allele-specific transcription factor binding is only displayed for neuro-relevant transcription factors. Perfect proxies are found in a large genomic range that includes genes adjacent to CRHR1.
Variants of CRHR1 predispose to panic disorder H Weber et al comparable physiological response patterns, including strong autonomic arousal. In contrast, anxious apprehension can be associated with defensive behaviors during the exposure to more proximal threats (mild body symptoms), both observed to be associated with moderate autonomic activation. 53 Animal models that are differentiating phasic and sustained fear 63 suggest that CRH is involved only in the latter, mainly by acting on the bed nucleus of the stria terminalis (BNST). [63] [64] [65] There is evidence that CRH-dependent BNST activation during anxiety states is mediated by CRHR1 activation. For example, in rats, administration of a CRHR1-specific antagonist blocked defensive behaviors during laboratory models of sustained but not phasic fear. 65 Moreover, CRH gene overexpression within the BNST increased sustained fear responses. 66 CRH overexpression was followed by a decreased CRHR1 receptor density within the BNST, suggesting that 'behavioral effects may be mediated by enhanced CRH receptor signaling or compensatory changes in CRH receptor density within these structures'. 66 Importantly, CRH overexpression impaired anxiety responses toward threat cues if administered prior to conditioning, and also, limbic CRHR1 was shown to be required for the enhancement of fear memory consolidation, 8 suggesting that CRHR1 may be important for the generalization of fear.
In line with these assumptions, fMRI findings indicate that risk allele carriers of rs17689918 demonstrate reduced differential conditioning in predominantly prefrontal cortices (where CRHR1 expression is reduced in risk allele carriers) and increased activation in brain regions relevant for fear processing such as the amygdala during processing of safety signals (again, CRHR1 expression is lower here in risk allele carriers), supporting the hypothesis of CRHR1 involvement in fear generalization (impaired differential conditioning owing to increased responses to the safety cue in the amygdala) in risk allele carriers. These data indicate that different top-down and bottom-up processes during fear conditioning 52 are affected by genetically driven CRHR1 expression differences in patients with PD/AG. Especially the generalization of fear and dysfunctional safety signal processing has been considered to be a relevant pathological mechanisms of PD/AG 67 and has been shown to be associated with the treatment response. 51 Altogether, these data indicate that variation in CHRH1 genotypes and subsequent expressional changes might contribute to the development of sustained fear owing to impaired safety signal processing and increased amygdala reactivity towards neural stimuli. Thus the neural network associated with the processing of threat in risk allele carriers seems to be biased toward fearful processing of neutral or ambiguous stimuli.
From rodent studies, it can therefore be inferred that genetic variation in CRHR1 might rather affect defensive stages mediating chronic anxious apprehension than defensive stages during acute For exact locations and statistics, please see Supplementary Tables S10 and S11. Risk allele carriers (A for rs17689918) demonstrated significantly reduced differential conditioning responses (CS+ (red)4CS − (blue); surface view, a) in predominantly left and bilateral frontal cortices compared with patients without risk alleles (GG for rs17689918). By contrast, risk allele carriers (A for rs17689918) in contrast to patients without risk alleles (GG for rs17689918) demonstrated increased activation in the amygdalae for the processing of the safety cues (CS − (blue); slice view, b). Note: In (b), amygdala activation has been explored using a region of interest analysis at an uncorrected voxel level threshold of P o0.05 (see Supplementary Table S11) . DLPFC, dorsolateral prefrontal cortex.
threat. Indeed, risk allele carriers not only reported high levels of anxiety during the BAT but also showed less escape behavior and decreased autonomic reactivity to the threat exposure. Previously, we found that during the task such a response pattern was rather associated with anxious apprehension than acute panic, with the latter one accompanied by strong autonomic reactions and, therefore, reflecting more imminent threat processing as supposed by animal models. 53 Additionally, risk allele carriers showed higher de-synchrony between the different indices of anxiety during the test. This de-synchrony has been found for those PD patients who are reporting more generalized agoraphobic anxiety and avoidance reflecting broader anxious apprehension but are also more severely impaired, show higher comorbidity, chronicity and general distress. 68 Accordingly, the rs16689918 risk allele was associated with pronounced depressive symptoms (Beck Depression Inventory-II), general distress (Brief Symptom Inventory) and, importantly, agoraphobic avoidance (Mobility Inventory) in the BAT sample (Supplementary Table S3 ). In sum, rs16689918 might increase the risk for PD by facilitating the development of more generalized anxious apprehension. In general, reduced CRHR1 expression-as a consequence of rs17689918 risk allele-may lead to generalized sustained fear particularly in the presence of ambiguous cues or context conditions. In summary, the present study provided compelling evidence for a role of the CRHR1 gene in the pathogenesis of PD. Allelic variation of the functional CRHR1 polymorphism rs17689918 has been found to predispose to PD, as reflected by emotion processing, psychophysiological parameters and psychometric traits. Our data indicate that CRHR1 has its role in PD in dysfunctional processing of safety cues and goes along with decreased rates of active avoidance, thus resembling states of sustained fear.
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